Patient experience is regulated language. We treat it as such.

What you are navigating.

• Claim restrictions tighten as patient testimony loosens. Reviews and forums describe outcomes the brand may not. Reading them rigorously is a compliance exercise, not a marketing one.
• Off-label and adjacent-use signals matter strategically. They shape future indications, suggest line extensions, and warn earlier than pharmacovigilance channels do.
• Audit trails are non-negotiable. Whatever insight is shown to medical affairs, regulatory, or commercial must be reproducible — source by source, version by version.

What we bring.

Three capabilities aligned with a regulated environment:

• Patient voice decomposition. Symptom, condition, expected outcome, comparator, satisfaction — extracted per record, with explicit confidence and source lineage.
• Off-label usage radar. Cross-source detection (forums, reviews, social) of usage patterns outside indication — flagged early, traced precisely, surfaced to medical affairs.
• Compliance-grade audit trails. Every insight ships with the verbatims, the model version, the source platforms, the date window — the artifact is reviewable the same way a clinical synthesis is.

What changes.

• Pharmacovigilance signals reach awareness alongside, not after, social mentions.
• Medical affairs and brand teams work from the same source-of-truth, not parallel decks.
• Regulatory submissions cite consumer evidence with the same rigor as clinical data.
• Brand claims survive legal review because they are grounded in cited testimony.
• The next indication conversation starts with patient narrative, not a search query.